Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Forte Biosciences ( (FBRX) ) just unveiled an update.
On June 24, 2025, Forte Biosciences announced a public offering of 5,630,450 shares of its common stock at $12.00 per share, along with pre-funded warrants for certain investors. The offering is expected to generate approximately $75 million in gross proceeds, with net proceeds estimated at $70 million, which will be used for working capital and corporate purposes, including clinical and preclinical development. The offering is set to close around June 26, 2025, and aims to support the company’s operations into 2027.
The most recent analyst rating on (FBRX) stock is a Buy with a $68.75 price target. To see the full list of analyst forecasts on Forte Biosciences stock, see the FBRX Stock Forecast page.
Spark’s Take on FBRX Stock
According to Spark, TipRanks’ AI Analyst, FBRX is a Underperform.
Forte Biosciences faces significant challenges with no revenue and increasing operational losses, leading to a weak financial performance. Technical analysis indicates a mixed outlook with bearish long-term trends. The negative P/E ratio and lack of dividend yield highlight valuation concerns. Without positive developments in these areas, the stock remains highly speculative and risky.
To see Spark’s full report on FBRX stock, click here.
More about Forte Biosciences
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and autoimmune-related diseases, with a key product candidate being FB102, an anti-CD122 monoclonal antibody.
Average Trading Volume: 51,894
Technical Sentiment Signal: Buy
Current Market Cap: $93.29M
Find detailed analytics on FBRX stock on TipRanks’ Stock Analysis page.